Sponsor

Incyte Corporation

Clinical research sponsor

Published trials78
Recruiting shown3
Roles2
SourceClinicalTrials.gov

Clinical trials

60 shown
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06179160 · lead sponsor · 2024-01-04
RECRUITING
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965 · lead sponsor · 2024-10-10
ACTIVE_NOT_RECRUITING
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationNCT06039384 · lead sponsor · 2023-12-28
TERMINATED
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveNCT05879822 · lead sponsor · 2023-10-30
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443 · lead sponsor · 2023-07-11
ACTIVE_NOT_RECRUITING
Study of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922 · lead sponsor · 2022-07-05
ACTIVE_NOT_RECRUITING
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationNCT05253807 · lead sponsor · 2022-04-29
COMPLETED
Study of INCB086550 in Select Solid TumorsNCT04629339 · lead sponsor · 2021-09-02
TERMINATED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsNCT04272034 · lead sponsor · 2021-03-26
TERMINATED
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsNCT04580485 · lead sponsor · 2021-02-03
COMPLETED
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerNCT04205812 · lead sponsor · 2020-09-11
COMPLETED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199 · lead sponsor · 2020-09-04
COMPLETED
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)NCT04203511 · lead sponsor · 2020-07-31
WITHDRAWN
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)NCT03920839 · lead sponsor · 2019-07-15
WITHDRAWN
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)NCT03679767 · lead sponsor · 2019-01-09
COMPLETED
A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077 · lead sponsor · 2018-09-24
COMPLETED
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)NCT03347123 · lead sponsor · 2018-03-21
TERMINATED
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid TumorsNCT03361228 · lead sponsor · 2018-03-01
TERMINATED
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)NCT03322566 · lead sponsor · 2018-01-09
COMPLETED
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung CancerNCT03348904 · lead sponsor · 2017-12-27
TERMINATED
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaNCT03374488 · lead sponsor · 2017-12-22
COMPLETED
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)NCT03342352 · lead sponsor · 2017-12-15
WITHDRAWN
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)NCT03322540 · lead sponsor · 2017-12-15
COMPLETED
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)NCT03260894 · lead sponsor · 2017-12-07
COMPLETED
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)NCT03361865 · lead sponsor · 2017-12-04
COMPLETED
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)NCT03358472 · lead sponsor · 2017-12-01
COMPLETED
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)NCT03085914 · lead sponsor · 2017-05-02
COMPLETED
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)NCT02959437 · lead sponsor · 2017-02-27
TERMINATED
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerNCT02917993 · lead sponsor · 2016-12-20
COMPLETED
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940 · lead sponsor · 2016-11-30
ACTIVE_NOT_RECRUITING
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsNCT02903914 · lead sponsor · 2016-09-14
COMPLETED
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesNCT02711137 · lead sponsor · 2016-05-18
TERMINATED
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesNCT02712905 · lead sponsor · 2016-05-05
TERMINATED
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsNCT02646748 · lead sponsor · 2016-01-25
COMPLETED
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesNCT02431260 · lead sponsor · 2015-04-14
TERMINATED
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)NCT02393248 · lead sponsor · 2015-02-27
TERMINATED
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaNCT02298153 · lead sponsor · 2015-01-27
TERMINATED
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)NCT02318277 · lead sponsor · 2015-01-05
COMPLETED
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsNCT02355431 · lead sponsor · 2014-12-01
WITHDRAWN
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)NCT02327078 · lead sponsor · 2014-11-26
COMPLETED
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerNCT02257619 · lead sponsor · 2014-09-24
TERMINATED
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersNCT02178722 · lead sponsor · 2014-07-17
COMPLETED
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerNCT02120417 · lead sponsor · 2014-05-01
TERMINATED
INCB047986 in Rheumatoid ArthritisNCT02151474 · lead sponsor · 2014-05-01
TERMINATED
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerNCT02119650 · lead sponsor · 2014-02-11
TERMINATED
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesNCT01929941 · lead sponsor · 2013-09-01
TERMINATED
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid ArthritisNCT01626573 · lead sponsor · 2012-03-01
COMPLETED
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast CancerNCT01254136 · lead sponsor · 2010-10-01
TERMINATED
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic DrugsNCT00902486 · lead sponsor · 2009-05-01
COMPLETED
Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 DiabeticsNCT00698230 · lead sponsor · 2008-05-01
COMPLETED
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 DiabetesNCT00698789 · lead sponsor · 2008-05-01
TERMINATED
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate CancerNCT00638378 · lead sponsor · 2008-02-01
TERMINATED
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid ArthritisNCT00550043 · lead sponsor · 2007-10-01
COMPLETED
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast CancerNCT00864175 · lead sponsor · 2007-07-01
TERMINATED
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic SubjectsNCT00478322 · lead sponsor · 2007-04-01
COMPLETED
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to DiabetesNCT00398619 · lead sponsor · 2006-11-01
COMPLETED
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected PatientsNCT00393120 · lead sponsor · 2006-10-01
COMPLETED
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIsNCT00300573 · lead sponsor · 2006-04-01
TERMINATED
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerNCT06616155 · collaborator · 2026-06-01
RECRUITING
Retifanlimab and Ruxolitinib In Solid MalignanciesNCT07219576 · collaborator · 2026-01-08
RECRUITING

Sponsor roles

lead sponsor58
collaborator20

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.